Post Content
Kenvue Inc. (NYSE:KVUE) is one of the 10 Best Stocks Under $20 to Buy According to Hedge Funds. On March 5, Barclays increased its price target on Kenvue Inc. (NYSE:KVUE) from $18 to $19 and kept its Equalweight rating.
Barclays analyst Lauren Lieberman pointed out that the company has performed relatively well in the classic consumer health categories, especially Self Care and Essential Health. However, the analyst also noted that the beauty segment requires a different strategy that is focused on premiumization and regimen-focused innovation. According to Barclays, Kenvue Inc. (NYSE:KVUE) has not yet fully developed this type of approach.
Earlier, on February 18, Canaccord Genuity also increased its price target on Kenvue Inc. (NYSE:KVUE) from $17 to $18 and maintained its Hold rating. This update came after the company reported Q4 and full-year 2025 results.
Q4 sales increased 3.2% year-over-year, beating the Street estimate of 0.4%. Organic sales rose 1.2% compared with the same period last year. All of Kenvue Inc.’s (NYSE:KVUE) segments reported growth in Q4. Additionally, adjusted EPS came in at $0.27, higher than the Street estimate of $0.22.
Kenvue Inc. (NYSE:KVUE) is a global consumer health company. The company’s brands include iconic names like Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena, and Tylenol.
While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Under-the-Radar Stocks to Buy According to Hedge Funds and 15 AI Stocks With Explosive Growth Potential.
Disclosure: None. Follow Insider Monkey on Google News.